Search results for " market"
Article
Developing a New Biologic Drug: Regulatory Challenges and Considerations
Click here to learn more >>
Key milestones and planning ahead for compliance when bringing a new biologic drug to market
Article
Cytiva Advances Fiber Chromatography Technology with New Launch
The time savings creates substantial cost savings and helps bring therapies to market faster, Cytiva said in a company press release. The technology has been selected and is currently used by more tha…
Article
Recent Development in Fibro Technology
This creates substantial cost savings and helps bring therapies to market faster. More than 300 academic labs and biomanufacturers have selected and successfully used Fibro technology.
Article
Akron Bio Will Install a Cytiva FlexFactory to Manufacture Plasmid DNA
Cytiva’s FlexFactory provides the speed and flexibility combined with the automation platform needed to meet the needs of such a dynamic market,” said Olivier Loeillot, senior vice-president, Bioproce…
Article
Cytiva Invests $500 Million Over 5 Years to Expand Global Capacity
Cytiva is also investing in a new facility in Grens, Switzerland, to manufacture single-use kits for its Sepax and Sefia cell processing systems for the cell and gene therapy market.
"We know from …
Article
EMA Confirms Standards for COVID-19 Treatment Evaluations
In the letter, the agency details steps to ensure a separation between persons giving scientific advice to a drug developer and persons evaluating a market authorization application. The letter states…
Article
Preparing for the Future Visions and Insights for Biomanufacturing
Yet, new market dynamics, such as growing competition from biosimilars and niche drugs targeting smaller patient populations, are reshaping how drugs are produced and sold.
Article
Process Development Webinar Library
Time to experiment, time to clinic, and time to market are becoming even more important for developers and manufacturers of biopharmaceuticals.
Cytiva’s library of on-demand webinars are de…
Article
Lentiviral Vector Upstream Process in Single-use Bioreactors
However, cost-effective manufacturing of lentiviral vectors at commercial scales has proven difficult and remains a pressing issue for the marketing of therapies that depend on their application.
Article
Production of Recombinant Adeno-associated Virus Vectors Using Microcarrier Culture of HEK293T Cells
As of March 2020, more than 4310 gene therapy clinical trials have been performed worldwide, with only 518 of them in Phase III and Phase IV. As the gene therapy projects enter clinical Phase III or g…